117 results about "Human papilloma virus infection" patented technology

Provided are adenoviral vectors for generating an immune response to antigen. The vectors comprise a transcription unit encoding a secretable polypeptide, the polypeptide comprising a secretory signal sequence upstream of a tumor antigen upstream of CD40 ligand, which is missing all or substantially all of the transmembrane domain rendering CD40L secretable. Also provided are methods of generating an immune response against cells expressing a tumor antigen by administering an effective amount of the invention vector. Further provided are methods of generating an immune response against cancer expressing a tumor antigen in an individual by administering an effective amount of the invention vector. Still further provided are methods of generating immunity to infection by human papilloma virus (HPV) by administering an effective amount of the invention vector which enocodes the E6 or E7 protein of HPV. The immunity generated is long term.

The invention discloses a preparation method for a biological agent for preventing and controlling human papilloma virus infection. The preparation method includes following steps: dissolving 3-hydroxy-phthalic anhydride HP into dimethyl sulfoxide DMSO to obtain saturated HP solution; dissolving beta-lactoglobulin beta-LG into 0.1M of sodium phosphate solution with pH (potential of hydrogen) of 8.5 to obtain protein solution with protein final concentration of 20mg / mL; and equally dividing the HP solution into five parts, adding the HP solution into the protein solution at every 12 minutes, shaking and mixing, adjusting pH of IMNaOH to be 8.5, leading the final concentration of anhydride in a reaction system to be 60mM, standing for 1 hour at the temperature of 25 DEG C, dialyzing by PBS (phosphate buffer solution) with pH of 7.4, performing filtration sterilization by a 0.45uM microfiltration membrane, and storing at the temperature of 4 DEG C so as to obtain a finished product. The biological agent has the advantages of capabilities of stopping HPV (human papilloma virus) from invading cells and stopping virus infection from spreading, safety, stability, low cost and the like.

Two RNases (ranpirnase and the second embodiment disclosed in U.S. Pat. No. 5,728,805) are tested against human papillomavirus infections. QRT-PCR assays indicate that the RNases have anti-viral activity against type 11 HPV.

Two RNases (ranpirnase and the second embodiment disclosed in U.S. Pat. No. 5,728,805) are tested against human papillomavirus infections. QRT-PCR assays indicate that the RNases have anti-viral activity against type 11 HPV.

The invention discloses a bioprotein dressing and a bioprotein invisible film for preventing and controlling human papilloma virus infection, relates to products for gynecological diseases and solves the problem of absence of medicines capable of effectively preventing and controlling HPV (human papilloma virus) infection in foreign and domestic markets. The bioprotein dressing comprises, by mass concentration, 0.05-1%o of JB protein, 1-3% of carbomer, 0.5-2% of green tea extracts, 1-5% of glycerol, 0.1-0.3% of triclosan and the balance water. The bioprotein invisible film comprises, by mass concentration, 0.05-1%o of JB protein, 0.05-1% of carbomer, 0.5-2% of green tea extracts, 1-5% of glycerol, 0.11-0.25% of enhanceparaben, 0.1-2% of phenoxyethanol and the balance water. The bioprotein dressing is anti-HPV biological agent, is good in biocompatibility, nonirritant, safe and free of side effect.

The invention relates to a fluorescent PCR detection method for diagnosing human papilloma virus (HPV) infection, and a kit which is prepared according to the detection method and is used to detect HPV genotype of a DNA sample isolated from a patient body for diagnosing whether the HPV genotype belongs to one of the 24 types of human papilloma virus and determining as high risk, moderate high-risk and low risk, and belongs to the field of life science and technology. The method comprises: taking fluorogenic quantitative PCR as the technological basic polymerase chain reaction (PCR), employing the kit comprising multiple-type-directing forward primers, reverse primers and probes, and under specific PCR conditions and in a reaction tube, simultaneously detecting DNA of 24 types of HPV such as HPV 6, 11, 16, 18, 31, 33, 35, 39, 42, 43, 44, 45, 51, 52, 53, 56, 58, 59, 66, 68, 73, 83, MM4 and cp8304. The kit and the detection method helps to simply accurately rapidly detect DNA of multiple types of HPV and reduce the cost, and is effectively applicable to prevention and screening of cervical cancers.

The present invention discloses the use of methyltestosterone as a novel pharmaceutical for treatment of anti-HPV infections, especially for treatment of verruca planae, condyloma acuminatum, and the relapse of these disorders. The therapeutic efficacy of the aforementioned indications proves satisfactory.

Use of Interleukin-20 for treating cervical cancer or cells infected with human papilloma virus. IL-20 can be administered alone or in conjunction with radiation or chemotherapeutic agents or surgical excision of the involved cells or lesions.

The invention is a series of synthetic virus-like particles comprising a heterologous conformational epitope useful in the characterization of human papillomavirus infection, and useful to vaccinate individual for protection against HPV 6 and HPV 11 infections, and assays employing the synthetic virus-like particles.

The invention relates to an antibody used for treatment of diseases, in particular to cervical cancer, related to human papilloma virus infection, and a preparation method and an application thereof.

A method of treating human papillomavirus (HPV), by administering a therapeutically effective amount of a primary cell-derived biologic to a patient infected with HPV, and inducing an immune response to HPV. A method of overcoming HPV-induced immune suppression of Langerhans cells (LC), by administering a therapeutically effective amount of a primary cell-derived biologic to a patient infected with HPV, and activating LC. A method of increasing LC migration towards lymph nodes, by administering a therapeutically effective amount of a primary cell-derived biologic to a patient infected with HPV, activating LC, and inducing LC migration towards lymph nodes. A method of generating immunity against HPV, by administering an effective amount of a primary cell derived biologic to a patient infected with HPV, generating immunity against HPV, and preventing new lesions from developing.